AHVAP Announces New Strategic Partnership in FDA TAP Program: Advancing Our Specialty and Strengthening Our Partnership

AHVAP Announces New Strategic Partnership in FDA TAP Program: Advancing Our Specialty and Strengthening Our Partnership



AHVAP Logo

ATLANTA, GA, UNITED STATES, September 23, 2026 / EINPresswire.com/ -- The Association of Healthcare Value Analysis Professionals (AHVAP) today announced that it has been welcomed as a participating non-FDA party in the U.S. Food and Drug Administration's Total Product Life Cycle Advisory Program (TAP) Pilot, administered by the Center for Devices and Radiological Health (CDRH).

The TAP Pilot is designed to give participating medical device developers, known as TAP Innovators, earlier and more frequent interactions with CDRH, along with more strategic engagement with non-FDA parties such as professional associations, clinicians, and payers. The goal is to support more rapid development of, and more rapid and widespread patient access to, safe, effective, high-quality medical devices of public health importance.

Through the program, TAP Innovators may request early engagement with non-FDA parties like AHVAP. The FDA anticipates these engagements may focus on strategies for clinical adoption, incorporation into professional guidelines, publication, coding, coverage and payment, and measurement of outcomes that matter to patients and healthcare providers.

For many innovators, the path from FDA authorization to real-world use runs directly through hospital value analysis committees. AHVAP members are the professionals who evaluate new products for clinical evidence, safety, cost, and operational impact before those products reach the bedside. By participating in TAP, AHVAP will help innovators understand what health systems need to see, earlier in the development process, so that promising technologies are better positioned for evidence-based adoption.

"Value analysis professionals see firsthand why some innovative devices reach patients quickly while others stall. This is an important moment for the value analysis profession. It reflects the

growing recognition that value analysis is an essential part of the healthcare innovation ecosystem, and it gives our members a meaningful voice in shaping how new technologies are evaluated and adopted. " said Dr. Hudson Garrett, Executive Director and Executive Vice President of AHVAP. "Participating in the FDA's TAP Pilot allows our profession to share that perspective at the point where it can make the greatest difference, during design and development, rather than after a product has already reached the market. We are honored to contribute to a program focused on getting safe, effective, high-value technologies to patients sooner."

AHVAP's participation in the TAP Pilot is voluntary, and engagements with TAP Innovators are conducted independently. AHVAP's involvement in any engagement does not constitute an endorsement of any specific device or company.

About AHVAP

The Association of Healthcare Value Analysis Professionals (AHVAP) is the preeminent professional organization dedicated to advancing the practice of healthcare value analysis. AHVAP supports professionals across hospitals, health systems, and the broader healthcare industry through education, certification, research, and advocacy, helping organizations make evidence-based decisions that improve patient outcomes, safety, and cost-effectiveness. Learn more at www.ahvap.org

Dr. Hudson Garrett Jr
Association of Healthcare Value Analysis Professionals
+1 888-400-6844
email us here

This press release can be viewed online at: https://www.einpresswire.com/article/944476427

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.